Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Perspectives on the development of imatinib and the future of cancer research

Perspectives on the development of imatinib and the future of cancer research La sker~DeB akey C L ini C a L me D i C a L resear C h awar D C O M M E N TA RY Perspectives on the development of imatinib and the future of cancer research Brian J Druker Imatinib: a personal history I am incredibly fortunate. To receive an award from the Lasker Foundation, with its preemi- nent jury, is indeed an honor. But the greatest reward is seeing patients every week in clinic who have benefitted from my work. The life expectancy of these patients was originally three to five years. They are now leading active and productive lives, and many have been with me for over ten years. My desire to pursue a career in oncology began when I was a medical student, when I took an elective course on the history of chemotherapy. We learned about the cure of childhood leukemia with combination che- motherapy and about the contributions of pioneers such as Sidney Farber and Lasker laureates Emil Frei and Emil Freireich. Despite these breakthroughs, I imagined there had to be a better way to treat cancer, and I wrote in my final essay that only through a molecular understanding http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Nature Medicine Springer Journals

Perspectives on the development of imatinib and the future of cancer research

Nature Medicine , Volume 15 (10) – Oct 1, 2009

Loading next page...
 
/lp/springer-journals/perspectives-on-the-development-of-imatinib-and-the-future-of-cancer-aY0W0xuvoE

References (25)

Publisher
Springer Journals
Copyright
Copyright © 2009 by Nature Publishing Group
Subject
Biomedicine; Biomedicine, general; Cancer Research; Metabolic Diseases; Infectious Diseases; Molecular Medicine; Neurosciences
ISSN
1078-8956
eISSN
1546-170X
DOI
10.1038/nm1009-1149
Publisher site
See Article on Publisher Site

Abstract

La sker~DeB akey C L ini C a L me D i C a L resear C h awar D C O M M E N TA RY Perspectives on the development of imatinib and the future of cancer research Brian J Druker Imatinib: a personal history I am incredibly fortunate. To receive an award from the Lasker Foundation, with its preemi- nent jury, is indeed an honor. But the greatest reward is seeing patients every week in clinic who have benefitted from my work. The life expectancy of these patients was originally three to five years. They are now leading active and productive lives, and many have been with me for over ten years. My desire to pursue a career in oncology began when I was a medical student, when I took an elective course on the history of chemotherapy. We learned about the cure of childhood leukemia with combination che- motherapy and about the contributions of pioneers such as Sidney Farber and Lasker laureates Emil Frei and Emil Freireich. Despite these breakthroughs, I imagined there had to be a better way to treat cancer, and I wrote in my final essay that only through a molecular understanding

Journal

Nature MedicineSpringer Journals

Published: Oct 1, 2009

There are no references for this article.